Hazard ratios (HRS) and 95% confidence intervals (CIs) for the primary efficacy endpoint by gender for targeted cardiovascular (CV) trials and categories. The HRs and 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of gender after adjustment for all other factors.